<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03170193</url>
  </required_header>
  <id_info>
    <org_study_id>20160338</org_study_id>
    <nct_id>NCT03170193</nct_id>
  </id_info>
  <brief_title>AMG 529 20160338 First in Human Study</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 529 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the safety and tolerability of AMG 529 following single, ascending doses
      administered subcutaneously (SC) or intravenously (IV) in healthy subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, ascending single-dose study in
      healthy subjects, which will be conducted at 1 to 3 sites in the United States.

      Approximately 48 subjects will enroll in 1 of 6 dose cohorts (8 per cohort).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Actual">November 24, 2017</completion_date>
  <primary_completion_date type="Actual">November 24, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized, double-blind, placebo-controlled, ascending single-dose study in healthy subjects, which will be conducted at 1 to 3 sites in the United States.
Approximately 48 subjects will enroll in 1 of 6 dose cohorts (8 per cohort).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events ; safety assessments</measure>
    <time_frame>Cohorts 1, 2 and 6 (up to 30 days); Cohort 3, 4 and 5 (up to 57 days)</time_frame>
    <description>Number of participants with treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety laboratory analytes</measure>
    <time_frame>Cohorts 1, 2 and 6 (up to 30 days); Cohort 3, 4 and 5 (up to 57 days)</time_frame>
    <description>Clinically significant changes in safety laboratory analytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Cohorts 1, 2 and 6 (up to 30 days); Cohort 3, 4 and 5 (up to 57 days)</time_frame>
    <description>Clinically significant changes in vital sigs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms (ECGs)</measure>
    <time_frame>Cohorts 1, 2 and 6 (up to 30 days); Cohort 3, 4 and 5 (up to 57 days)</time_frame>
    <description>Clinically significant changes in ECGs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter of maximum observed concentration</measure>
    <time_frame>Cohorts 1, 2 and 6 (up to 30 days); Cohort 3, 4 and 5 (up to 57 days)</time_frame>
    <description>PK effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of time of of maximum observed concentration (tmax)</measure>
    <time_frame>Cohorts 1, 2 and 6 (up to 30 days); Cohort 3, 4 and 5 (up to 57 days)</time_frame>
    <description>PK effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of area under the concentration time curve (AUC)</measure>
    <time_frame>Cohorts 1, 2 and 6 (up to 30 days); Cohort 3, 4 and 5 (up to 57 days)</time_frame>
    <description>PK effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALP levels</measure>
    <time_frame>Cohorts 1, 2 and 6 (up to 30 days); Cohort 3, 4 and 5 (up to 57 days)</time_frame>
    <description>PD Parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>Cohorts 1, 2 and 6 (up to 30 days); Cohort 3, 4 and 5 (up to 57 days)</time_frame>
    <description>PD Paramater: Lipid levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C</measure>
    <time_frame>Cohorts 1, 2 and 6 (up to 30 days); Cohort 3, 4 and 5 (up to 57 days)</time_frame>
    <description>PD Parameter: Lipid levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-C</measure>
    <time_frame>Cohorts 1, 2 and 6 (up to 30 days); Cohort 3, 4 and 5 (up to 57 days)</time_frame>
    <description>PD Parameter: Lipid levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Cohorts 1, 2 and 6 (up to 30 days); Cohort 3, 4 and 5 (up to 57 days)</time_frame>
    <description>PD Parameter: Lipid levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cardiovascular</condition>
  <arm_group>
    <arm_group_label>AMG 529 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 529 of different dose levels administered to healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of calculated volume to match experimental drug administered to healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 529</intervention_name>
    <description>Ascending single doses of AMG 529</description>
    <arm_group_label>AMG 529 Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Calculated volume to match experimental drug</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy men and women ≥ 18 to ≤ 55 years old with no history or evidence of clinically
             relevant medical disorders

          2. Body mass index (BMI) between 18 and 32 kg/m2, inclusive, at screening

          3. Women must be of non-reproductive potential as defined in protocol

          4. Other inclusion criteria may apply

        Exclusion Criteria:

          1. Currently receiving treatment in another investigational device or drug study, or less
             than 30 days or 5 half-lives (whichever is longer), since ending treatment on another
             investigational device or drug study(s) prior to receiving the first dose of
             investigational product

          2. Women who are lactating/breastfeeding or who plan to breastfeed while on study through
             90 days after receiving the dose of investigational product

          3. Men with partners who are pregnant or planning to become pregnant while the subject is
             on study through 90 days after receiving the dose of investigational product

          4. Positive pregnancy test at screening or day -1

          5. Other exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

